BioHarvest Sciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY Revenue (est.)
$42.9Mnext fiscal year
FY EPS (est.)
-$0.41next fiscal year
Monitoring Framework
Key Performance Indicators
D2C Active Users Quarterly90K
Consolidated Gross Margin Quarterly59.0%
CDMO Stage 2 Contract Value Quarterly1.2M
Watch Items
- D2C Marketing Reset and LTV to CAC OptimizationTrigger: Quarter-over-quarter D2C revenue growth recovery in Q2-Q4 2026Action: Evaluate marketing spend efficiency and customer acquisition cost trends if growth remains flat.
- New Manufacturing Facility Operational TimelineTrigger: Operational readiness in H2 2027Action: Monitor CapEx ramp-up during Q2 and Q3 2026 to ensure construction milestones are met.
Research as of 19 Jun 2026